Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1945 2
1946 1
1947 3
1952 1
1957 3
1960 1
1962 1
1964 2
1965 2
1966 1
1967 1
1968 1
1969 1
1970 2
1971 1
1972 2
1973 4
1977 2
1978 3
1979 1
1980 1
1983 1
1984 6
1985 2
1986 1
1988 1
1991 1
1992 5
1996 2
1997 3
2004 2
2006 1
2007 3
2008 4
2009 4
2010 4
2011 6
2012 2
2013 4
2014 7
2015 9
2016 10
2017 14
2018 12
2019 8
2020 8
2021 14
2022 15
2023 17
2024 11
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Hughes TP, et al. Among authors: ross dm. N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328. N Engl J Med. 2019. PMID: 31826340 Free PMC article. Clinical Trial.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR. Wylie AA, et al. Among authors: ross dm. Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22. Nature. 2017. PMID: 28329763
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Duncavage EJ, et al. Among authors: ross dm. Blood. 2022 Nov 24;140(21):2228-2247. doi: 10.1182/blood.2022015853. Blood. 2022. PMID: 36130297 Free PMC article.
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.
Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong ASM, Shortt J, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza A, Wright M, Harrup R, Forsyth C, Filshie R, Lane S, Browett P, Grove C, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. Yeung DT, et al. Among authors: ross dm. Blood. 2024 Nov 7;144(19):1993-2001. doi: 10.1182/blood.2024024657. Blood. 2024. PMID: 39102630 Free article.
The Evolution of Treatment-Free Remission.
Hughes TP, Yong AS, Ross DM. Hughes TP, et al. Among authors: ross dm. Blood. 2025 Jan 6:blood.2024026310. doi: 10.1182/blood.2024026310. Online ahead of print. Blood. 2025. PMID: 39761414
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.
Zerella JR, Homan CC, Arts P, Lin X, Spinelli SJ, Venugopal P, Babic M, Brautigan PJ, Truong L, Arriola-Martinez L, Moore S, Hollins R, Parker WT, Nguyen H, Kassahn KS, Branford S, Feurstein S, Larcher L, Sicre de Fontbrune F, Demirdas S, de Munnik S, Antoine-Poirel H, Brichard B, Mansour S, Gordon K, Wlodarski MW, Koppayi A, Dobbins S, Mutsaers PGNJ, Nichols KE, Oak N, DeMille D, Mao R, Crawford A, McCarrier J, Basel D, Flores-Daboub J, Drazer MW, Phillips K, Poplawski NK, Birdsey GM, Pirri D, Ostergaard P, Simons A, Godley LA, Ross DM, Hiwase DK, Soulier J, Brown AL, Carmichael CL, Scott HS, Hahn CN. Zerella JR, et al. Among authors: ross dm. Blood. 2024 Oct 24;144(17):1765-1780. doi: 10.1182/blood.2024024607. Blood. 2024. PMID: 38991192 Free PMC article.
Single cells tell multiple tales in CML.
Ross DM. Ross DM. Blood. 2023 Jun 1;141(22):2668-2670. doi: 10.1182/blood.2023020165. Blood. 2023. PMID: 37261852 Free article. No abstract available.
How much imatinib is enough?
Ross DM. Ross DM. Br J Haematol. 2021 May;193(4):699-700. doi: 10.1111/bjh.17444. Epub 2021 Apr 19. Br J Haematol. 2021. PMID: 33876424 No abstract available.
204 results